KFAS
ABUS icon

Keating Financial Advisory Services’s Arbutus Biopharma ABUS Stock Holding History

Keating Financial Advisory Services’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,029
Closed -$4.95K – 2562
2025
Q4 		$4.95K Buy
+1,029
New +$4.63K ﹤0.01% 1285

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Keating Financial Advisory Services's ABUS Position: Q1 2026 in Review

Keating Financial Advisory Services sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 1,029 shares — an estimated $4.95K sold.

Keating Financial Advisory Services first reported a position in ABUS in Q4 2025 and held it in 1 quarter. The position peaked at $4.95K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Keating Financial Advisory Services reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 1,029 Arbutus Biopharma shares in Q1 2026, an estimated $4.95K.
  • Keating Financial Advisory Services first reported a position in Arbutus Biopharma in Q4 2025 and held it in 1 quarter.
  • Keating Financial Advisory Services's Arbutus Biopharma position peaked at $4.95K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.